Physician Burnout, Selpercatinib Approval, COVID-19 NewsMay 18, 2020 | Oncology All Specialties The Most and Least Burned Out Physicians by Specialty Physician burnout is on the rise. With emergency medicine physicians reporting a staggering 65% burnout rate, it’s clear that measures need to be taken to address this growing issue. Read full article Hematology FDA Approves Selpercatinib as First Therapy for Certain Patients With Lung, Thyroid Cancers Based on the results of an open-label trial, selpercatinib (Retevmo) becomes the first targeted therapy to be granted accelerated approval by the FDA for use in patients with cancer who have certain tumors that have an alteration (mutation or fusion) in the RET gene. Read full article Gastroenterology Anetumab Ravtansine Shows Encouraging Activity in Multiple Solid Tumor Types In this Journal of Clinical Oncology study, anetumab ravtansine yielded manageable safety, tolerability, pharmacokinetics, and clinical activity in a study of 148 heavily pretreated patients with mesothelin-expressing solid tumors. Read full article